Spero Therapeutics (Nasdaq: SPRO) is a multi-asset pre-commercial stage biopharmaceutical company in Cambridge, Mass. We are highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnological and biopharmaceutical experts. The company has a pipeline of novel and highly differentiated antibacterial and rare disease product candidates focused on patients' unmet needs with multi-drug resistant (MDR) bacterial infections. 

Biotechnology

Spero Therapeutics

Sath Shukla

Kristyn McCandless

Esther Rajavelu

Ed Sopp

Troy Lister

Timothy Keutzer

Thomas Parr

Susan Redican

Shekman Wong

Kathy Burke

Laura McGinn

Nivedita Bhatt

Ilia Terova

Akash Jain

Jamie Brady

Myriah Satterfield

Indu Lakhani

Kamal Hamed

Frank E. Thomas

Tregoning Prior

Scott Jackson

John C. Pottage

David Musselman

Jay Blackington

Cristina Larkin

Leadership Team

Directors Team

Clinical and Research Operations

Business Development & Market Access

Operations Team

Management Team

Human Resources

Regulatory Affairs and Legal

Teams at Spero Therapeutics